It was a busy week for Australia's top brokers. This has led to a number of broker notes being released.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:
Hub24 Ltd (ASX: HUB)
According to a note out of Bell Potter, its analysts have retained their buy rating and $110.00 price target on this investment platform provider's shares. The broker highlights that despite early weakness, global equity markets recovered and posted outsized returns for the June quarter. In light of this, Bell Potter has upgraded its model to reflect strong positive mark-to-markets. Outside this, the broker believes that a heavy decline since its November peak, despite earnings upgrades and further positive adjustments yet to flow through, has created a buying opportunity for investors. The Hub24 share price ended the week at $81.04.
Northern Star Resources Ltd (ASX: NST)
A note out of Citi reveals that its analysts have retained their buy rating and $29.70 price target on this gold miner's shares. The broker was pleased with Northern Star's quarterly update, which revealed gold sales comfortably ahead of expectations during the fourth quarter. It notes that this helped take Northern Star's gold sales beyond its revised guidance for FY 2026. As a result of this strong performance, Citi continues to see plenty of value in the company's shares at current levels. The Northern Star share price was fetching $22.16 at Friday's close.
ResMed Inc. (ASX: RMD)
Analysts at Morgans have retained their buy rating and $41.72 price target on this sleep disorder treatment company's shares. According to the note, the broker highlights that ResMed's shares have de-rated to just 16 times forward earnings. This is its lowest valuation in over a decade and comes despite the market continuing to forecast double-digit earnings per share growth. And while there are risks from GLP-1 therapies, an oral OSA therapy, and the potential re-entry of a key competitor next year, Morgans points out that current industry data and its operating performance provide limited evidence of a material deterioration in underlying demand. The ResMed share price ended the week at $30.50.
The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.
Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24 and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026